secwatch.observer — SEC 8-K summary
======================================

Issuer:     INOVIO PHARMACEUTICALS, INC. (INO)
CIK:        0001055726
Form:       8-K
Filed at:   2025-12-29T23:59:59+00:00
Accession:  0001193125-25-332322
Event type: regulatory
Sentiment:  neutral
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA accepts INOVIO's BLA for INO-3107; standard review, PDUFA Oct 2026, but flags accelerated approval issue
--------------------------------------------------------------------------------

- BLA accepted for review; FDA classified as standard; no advisory committee planned.
- PDUFA goal date October 30, 2026.
- FDA preliminary conclusion: inadequate info to justify accelerated approval eligibility.
- Company to request meeting with FDA to discuss accelerated approval; not pursuing traditional pathway.
- INO-3107 is investigational immunotherapy for recurrent respiratory papillomatosis (RRP) in adults.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1055726/000119312525332322/0001193125-25-332322-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1055726/000119312525332322/d78035d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-332322

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer